Skip to content
2000
Volume 26, Issue 8
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Cirrhosis is a very serious, gradual liver disease characterized by the overproduction of collagen and scarring, which together may result in liver failure or hepatocellular cancer. It typically develops based on fibrosis, which may be reversible when diagnosed in its initial stages. Viral hepatitis, alcohol, non-alcoholic fatty liver disease, and drug-induced hepatotoxicity are some of the etiologies of the disease. It is worth noting that about half of the cases of hepatic damage in patients are known to be caused by drug-induced liver injury. The existence of the pathophysiological complexity and therapeutic reactions of cirrhosis requires experimental models that are reliable. This review gives insight into the different , , and operative animal models employed to cause hepatic injury by application of chemicals, drugs, dietary, and bile duct ligation particulars. The focus is on the mechanistic understanding of the actions of hepatotoxic substances, their involvement in oxidative stress, mitochondrial pathology, and the inflammatory process. Each model is critically discussed in terms of its advantages, limitations, and translational relevance.Additionally, this work highlights emerging alternatives, such as organ-on-a-chip systems, 3D co-cultures, and hepatic bioengineered tissues, as solutions that aim to reduce animal use and increase physiological relevance. The review also discusses biomarkers, histopathological endpoints, and important molecular players in hepatic fibrosis and cirrhosis. The review also examines data from preclinical studies of hepatoprotective substances and modulators of fibrosis, as it facilitates the integration of data from various experimental platforms. The next steps involve personalized pathology based on decellularized liver scaffolding and patient cells, aiming to better determine clinical outcomes and treatment responses.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002394147251007105422
2025-11-04
2026-03-02

  • From This Site

    /content/journals/cdm/10.2174/0113892002394147251007105422
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ThamE.K.J. TanD.J.H. DanpanichkulP. NgC.H. SynN. KohB. LimR.Y.Z. WijarnpreechaK. TengM.L.P. NahB.K.Y. SimB.K.L. ChengX. ZhangZ. MitraK. NakamuraT. TakahashiH. LoombaR. ZhengM.H. MuthiahM. HuangD.Q. The global burden of cirrhosis and other chronic liver diseases in 2021.Liver Int.2025453e7000110.1111/liv.70001 39927433
     [Google Scholar]
  2. SacchiM. BansalR. RouwkemaJ. Bioengineered 3D models to recapitulate tissue fibrosis.Trends Biotechnol.202038662363610.1016/j.tibtech.2019.12.010 31952833
     [Google Scholar]
  3. El HusseinM.T. RankinJ.A. ThenK.L. Mnemonic to assist in management of liver cirrhosis.J. Nurse Pract.2018141073273810.1016/j.nurpra.2018.08.032
     [Google Scholar]
  4. FengG. ValentiL. WongV.W.S. FouadY.M. YilmazY. KimW. SebastianiG. YounossiZ.M. Hernandez-GeaV. ZhengM.H. Recompensation in cirrhosis: Unravelling the evolving natural history of nonalcoholic fatty liver disease.Nat. Rev. Gastroenterol. Hepatol.2024211465610.1038/s41575‑023‑00846‑4 37798441
     [Google Scholar]
  5. AlaqailiH.I. AljuraysanA.I. HawsawiR.M.A. Review on liver cirrhosis complications and treatment.Egypt. J. Hosp. Med.20176983092310310.12816/0042860
     [Google Scholar]
  6. HuangD.Q. TerraultN.A. TackeF. GluudL.L. ArreseM. BugianesiE. LoombaR. Global epidemiology of cirrhosis — aetiology, trends and predictions.Nat. Rev. Gastroenterol. Hepatol.202320638839810.1038/s41575‑023‑00759‑2 36977794
     [Google Scholar]
  7. MondalD. DasK. ChowdhuryA. epidemiology of liver Diseases in india.Clin. Liver Dis. (Hoboken)202219311411710.1002/cld.1177 35355840
     [Google Scholar]
  8. Garcia-CortesM. Robles-DiazM. StephensC. Ortega-AlonsoA. LucenaM.I. AndradeR.J. Drug induced liver injury: An update.Arch. Toxicol.202094103381340710.1007/s00204‑020‑02885‑1 32852569
     [Google Scholar]
  9. Crespo YanguasS. CogliatiB. WillebrordsJ. MaesM. ColleI. van den BosscheB. de OliveiraC.P.M.S. AndrausW. AlvesV.A. LeclercqI. VinkenM. Experimental models of liver fibrosis.Arch. Toxicol.20169051025104810.1007/s00204‑015‑1543‑4 26047667
     [Google Scholar]
  10. NdakotsuA. NdukaT.C. AgrawalS. AsukaE. Cirrhotic cardiomyopathy: Comprehensive insights into pathophysiology, diagnosis, and management.Heart Fail. Rev.202530473974810.1007/s10741‑025‑10500‑7 40069401
     [Google Scholar]
  11. XieX.Y. BenmassaoudA. Advances in the diagnosis and management of clinically significant portal hypertension in cirrhosis: A narrative review.World J. Hepatol.202517610476110.4254/wjh.v17.i6.104761 40606915
     [Google Scholar]
  12. Guixé-MuntetS. Quesada-VázquezS. Gracia-SanchoJ. Pathophysiology and therapeutic options for cirrhotic portal hypertension.Lancet Gastroenterol. Hepatol.20249764666310.1016/S2468‑1253(23)00438‑7 38642564
     [Google Scholar]
  13. Ferguson TollJ. SolàE. PerezM.A. PianoS. ChengA. SubramanianA.K. KimW.R. Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda.Hepatol. Commun.2024810e053910.1097/HC9.0000000000000539 39365139
     [Google Scholar]
  14. KasperV.L. AssisD.N. Pathophysiology of cystic fibrosis liver disease.Pediatr. Pulmonol.202459S1S98S10610.1002/ppul.26869 39105342
     [Google Scholar]
  15. MyersS. GuptaD.K. IzzyM. The clinical relevance of the new criteria for cirrhotic cardiomyopathy and future directions.Liver Transpl.202531452153010.1097/LVT.0000000000000458 39185907
     [Google Scholar]
  16. JagdishR.K. RoyA. KumarK. PremkumarM. SharmaM. RaoP.N. ReddyD.N. KulkarniA.V. Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure.Front. Med. (Lausanne)202310106007310.3389/fmed.2023.1060073 37396918
     [Google Scholar]
  17. DesaiM.S. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy.Anal. Biochem.202263611438810.1016/j.ab.2021.114388 34587512
     [Google Scholar]
  18. DharD. BaglieriJ. KisselevaT. BrennerD.A. Mechanisms of liver fibrosis and its role in liver cancer.Exp. Biol. Med. (Maywood)202024529610810.1177/1535370219898141 31924111
     [Google Scholar]
  19. ThawleyV. Acute liver injury and failure.Vet. Clin. North Am. Small Anim. Pract.201747361763010.1016/j.cvsm.2016.11.010 28065578
     [Google Scholar]
  20. NewcomerB.W. Toxicologic insults to the bovine liver.Vet. Clin. North Am. Food Anim. Pract.202238342143210.1016/j.cvfa.2022.07.003 36243463
     [Google Scholar]
  21. ShehuA.I. MaX. VenkataramananR. Mechanisms of drug-induced hepatotoxicity.Clin. Liver Dis.2017211355410.1016/j.cld.2016.08.002 27842774
     [Google Scholar]
  22. BattleA. MuddJ. AhlenstielG. KaloE. Liver cirrhosis: Evolving definitions, and recent advances in diagnosis, prevention and management.Livers2025532810.3390/livers5030028
     [Google Scholar]
  23. ZhongH.J. ChenJ.Y. WuW.M. HeX.X. ZhanY.Q. Clinical significance of platelet-to-white blood cell ratio in patients with Wilson disease: a retrospective cohort study.PeerJ202513e1937910.7717/peerj.19379 40321812
     [Google Scholar]
  24. DallioM. RomeoM. VaiaP. AulettaS. MammoneS. CipulloM. SapioL. RagoneA. NiosiM. NaviglioS. FedericoA. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in metabolic dysfunction-associated steatotic liver disease-induced cirrhosis.World J. Gastroenterol.202430768570410.3748/wjg.v30.i7.685 38515952
     [Google Scholar]
  25. CiovicescuL.M. ClichiciS.V. SimedreaR.A. CiovicescuF. LupanS.C. SabăuL.I. ToaderA.M. MocanT. Innovative prophylactic and therapeutic approaches in liver cirrhosis.Physiol. Int.2024111111810.1556/2060.2024.00339 38421387
     [Google Scholar]
  26. LiH. DaiR. HuangY. ZhongJ. YanQ. YangJ. HuK. ZhongY. [18F]AlF-ND-bisFAPI PET imaging of fibroblast activation protein as a biomarker to monitor the progression of liver fibrosis.Hepatol. Commun.202484e040710.1097/HC9.0000000000000407 38466884
     [Google Scholar]
  27. ShenJ. LiZ. LiuX. ZhengM. ZhangP. ChenY. TianQ. TianW. KouG. CuiY. XuB. ZhaiY. LiW. GuoX. QiuJ. LiC. HeR. LiL. MaC. LiY. ZuoX. YuanD. LiS. Sensing of liver‐derived nicotinamide by intestinal group 2 innate lymphoid cells links liver cirrhosis and ulcerative colitis susceptibility.Adv. Sci. (Weinh.)20241138240427410.1002/advs.202404274 39119946
     [Google Scholar]
  28. KostallariE. SchwabeR.F. GuillotA. Inflammation and immunity in liver homeostasis and disease: A nexus of hepatocytes, nonparenchymal cells and immune cells.Cell. Mol. Immunol.2025212110.1038/s41423‑025‑01313‑7 40595432
     [Google Scholar]
  29. ChukwumaC. Human hepatocytes response to pathological shifts in liver fibrosis.J. Med. Res.2024101374110.31254/jmr.2024.10108
     [Google Scholar]
  30. PemmasaniG. TremaineW. KaragozianR. JohnS. Impact of cirrhosis etiology on the risk for venous thromboembolism.Dig. Dis. Sci.20246972691269810.1007/s10620‑024‑08440‑7 38700633
     [Google Scholar]
  31. KezerC.A. BerzigottiA. FortuneB.E. SimonettoD.A. Drug treatments to prevent first decompensation in cirrhosis.Hepatology2024109710.1097/HEP.0000000000001117 39378416
     [Google Scholar]
  32. DaiE.H. GuoX.R. WangJ.T. HuQ.G. LiJ.H. TangQ.Y. ZuH.M. HuanH. WangY. GaoY.F. HuG.Q. LiW. LiuZ.J. MaQ.P. SongY.L. YangJ.H. ZhuY. HuangS.D. MengZ.J. BaiB. ChenY.P. GaoC. HuangM.X. JinS.Q. LuM.Z. XuZ. ZhangQ.H. ZhengS. ZengQ.L. QiX.L. Investigate of the etiology and prevention status of liver cirrhosis.Zhonghua Yi Xue Za Zhi202310312913919 36973219
     [Google Scholar]
  33. SmithG.P. Animal models of fibrosis in human disease. Animal Models for the Study of Human Disease.Acadeic Press201343545810.1016/B978‑0‑12‑415894‑8.00019‑1
     [Google Scholar]
  34. AhmadF. TabassumN. Experimental models used for the study of antihepatotoxic agents.J. Acute Dis.201212858910.1016/S2221‑6189(13)60021‑9
     [Google Scholar]
  35. Delgado-MontemayorC. Cordero-PérezP. Salazar-ArandaR. Models of hepatoprotective activity assessment.Med. Univ.2015176922210.1016/j.rmu.2015.10.002
     [Google Scholar]
  36. RahmouniF. HamdaouiL. BadraouiR. RebaiT. Protective effects of Teucrium polium aqueous extract and ascorbic acid on hematological and some biochemical parameters against carbon tetrachloride (CCl 4) induced toxicity in rats.Biomed. Pharmacother.201791434810.1016/j.biopha.2017.04.071 28448868
     [Google Scholar]
  37. RahmouniF. BadraouiR. Ben-NasrH. BardakciF. ElkahouiS. SiddiquiA.J. SaeedM. SnoussiM. SaoudiM. RebaiT. Pharmacokinetics and therapeutic potential of Teucrium polium against liver damage associated hepatotoxicity and oxidative injury in rats: Computational, biochemical and histological studies.Life2022127109210.3390/life12071092 35888180
     [Google Scholar]
  38. RahmouniF. BadraouiR. AmriN. ElleuchA. El-FekiA. RebaiT. SaoudiM. Hepatotoxicity and nephrotoxicity in rats induced by carbon tetrachloride and the protective effects of Teucrium polium and vitamin C.Toxicol. Mech. Methods201929531332110.1080/15376516.2018.1519864 30676168
     [Google Scholar]
  39. IlaiyarajaN. KhanumF. Amelioration of alcohol-induced hepatotoxicity and oxidative stress in rats by Acorus calamus.J. Diet. Suppl.20118433134510.3109/19390211.2011.615805 22432772
     [Google Scholar]
  40. GaoB. SekiE. BrennerD.A. FriedmanS. CohenJ.I. NagyL. SzaboG. ZakhariS. Innate immunity in alcoholic liver disease.Am. J. Physiol. Gastrointest. Liver Physiol.20113004G516G52510.1152/ajpgi.00537.2010 21252049
     [Google Scholar]
  41. SimeonovaR. Kondeva-BurdinaM. VitchevaV. MitchevaM. Some in vitro/in vivo chemically-induced experimental models of liver oxidative stress in rats.BioMed Res. Int.201420141610.1155/2014/706302 24551852
     [Google Scholar]
  42. JaeschkeH. GoresG.J. CederbaumA.I. HinsonJ.A. PessayreD. LemastersJ.J. Mechanisms of hepatotoxicity.Toxicol. Sci.200265216617610.1093/toxsci/65.2.166 11812920
     [Google Scholar]
  43. MoustafaA.H.A. AliE.M.M. MoselheyS.S. ToussonE. El-SaidK.S. Effect of coriander on thioacetamide-induced hepatotoxicity in rats.Toxicol. Ind. Health201430762162910.1177/0748233712462470 23042592
     [Google Scholar]
  44. AkhtarT. SheikhN. An overview of thioacetamide-induced hepatotoxicity.Toxin Rev.2013323434610.3109/15569543.2013.805144
     [Google Scholar]
  45. LowT.Y. LeowC.K. Salto-TellezM. ChungM.C.M. A proteomic analysis of thioacetamide‐induced hepatotoxicity and cirrhosis in rat livers.Proteomics20044123960397410.1002/pmic.200400852 15526343
     [Google Scholar]
  46. ChooiK.F. Kuppan RajendranD.B. PhangS.S.G. TohH.H. The dimethylnitrosamine induced liver fibrosis model in the rat.J. Vis. Exp.2016112e54208 27340889
     [Google Scholar]
  47. KitamuraK. NakamotoY. AkiyamaM. FujiiC. KondoT. KobayashiK. KanekoS. MukaidaN. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis.Lab. Invest.200282557158310.1038/labinvest.3780452 12003998
     [Google Scholar]
  48. DingZ. ZhuoL. Attenuation of hepatic fibrosis by an imidazolium salt in thioacetamide‐induced mouse model.J. Gastroenterol. Hepatol.201328118820110.1111/j.1440‑1746.2012.07265.x 22989190
     [Google Scholar]
  49. SharmaA. SharmaV. KansalL. Amelioration of lead-induced hepatotoxicity by Allium sativum extracts in Swiss albino mice.Libyan J. Med.201051462110.3402/ljm.v5i0.4621 28156294
     [Google Scholar]
  50. SharmaV. PandeyD. Protective role of Tinospora cordifolia against lead-induced hepatotoxicity.Toxicol. Int.2010171121710.4103/0971‑6580.68343 21042467
     [Google Scholar]
  51. El-NekeetyA.A. El-KadyA.A. SolimanM.S. HassanN.S. Abdel-WahhabM.A. Protective effect of Aquilegia vulgaris (L.) against lead acetate-induced oxidative stress in rats.Food Chem. Toxicol.20094792209221510.1016/j.fct.2009.06.019 19531368
     [Google Scholar]
  52. GanaiA.A. HusainM. Genistein attenuates D-GalN induced liver fibrosis/chronic liver damage in rats by blocking the TGF-β/Smad signaling pathways.Chem. Biol. Interact.2017261808510.1016/j.cbi.2016.11.022 27876602
     [Google Scholar]
  53. TekkesinN. TagaY. SavA. AlmaataI. IbrisimD. Induction of HGF and VEGF in hepatic regeneration after hepatotoxin-induced cirrhosis in mice.Hepatogastroenterology201158107-108971979 21830426
     [Google Scholar]
  54. GanaiA.A. GanaieI.A. VermaN. FarooqiH. Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage.Chem. Biol. Interact.201626011712810.1016/j.cbi.2016.11.008 27836788
     [Google Scholar]
  55. PanY. CaoM. YouD. QinG. LiuZ. Research progress on the animal models of drug‐induced liver injury: current status and further perspectives.BioMed Res. Int.20192019111210.1155/2019/1283824 31119149
     [Google Scholar]
  56. TaguchiK. TokunoM. YamasakiK. KadowakiD. SeoH. OtagiriM. Establishment of a model of acetaminophen-induced hepatotoxicity in different weekly-aged ICR mice.Lab. Anim.201549429430110.1177/0023677215573041 25675952
     [Google Scholar]
  57. JaeschkeH. XieY. McGillM.R. Acetaminophen-induced liver injury: from animal models to humans.J. Clin. Transl. Hepatol.201423153161 26355817
     [Google Scholar]
  58. NiH.M. BockusA. BoggessN. JaeschkeH. DingW.X. Activation of autophagy protects against acetaminophen-induced hepatotoxicity.Hepatology201255122223210.1002/hep.24690 21932416
     [Google Scholar]
  59. BoelsterliU.A. LeeK.K. Mechanisms of isoniazid‐induced idiosyncratic liver injury: Emerging role of mitochondrial stress.J. Gastroenterol. Hepatol.201429467868710.1111/jgh.12516 24783247
     [Google Scholar]
  60. MetushiI.G. NakagawaT. UetrechtJ. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: Humans are more like mice than rats.Chem. Res. Toxicol.201225112567257610.1021/tx300341r 23016703
     [Google Scholar]
  61. MetushiI.G. UetrechtJ. Isoniazid-induced liver injury and immune response in mice.J. Immunotoxicol.201411438339210.3109/1547691X.2013.860644 24303880
     [Google Scholar]
  62. NwiduL.L. TemeR.E. Hot aqueous leaf extract of Lasianthera africana (Icacinaceae) attenuates rifampicin-isoniazid-induced hepatotoxicity.J. Integr. Med.201816426327210.1016/j.joim.2018.05.001 29776838
     [Google Scholar]
  63. GuoY.X. XuX.F. ZhangQ.Z. LiC. DengY. JiangP. HeL.Y. PengW.X. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.Toxicol. Mech. Methods201525538238710.3109/15376516.2015.1033074 25886055
     [Google Scholar]
  64. YaoX.M. LiY. LiH.W. ChengX.Y. LinA.B. QuJ.G. Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice.Can. J. Physiol. Pharmacol.20169411810.1139/cjpp‑2015‑0074 26640164
     [Google Scholar]
  65. DengZ. YanS. HuH. DuanZ. YinL. LiaoS. SunY. YinD. LiG. Proteomic profile of carbonylated proteins in rat liver: Discovering possible mechanisms for tetracycline‐induced steatosis.Proteomics201515114815910.1002/pmic.201400115 25332112
     [Google Scholar]
  66. ChoiY.J. LeeC.H. LeeK.Y. JungS.H. LeeB.H. Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice.Toxicol. Sci.2015145227328210.1093/toxsci/kfv049 25745068
     [Google Scholar]
  67. LiuX. HuangD. LaiC. ZengG. QinL. ZhangC. YiH. LiB. DengR. LiuS. ZhangY. Recent advances in sensors for tetracycline antibiotics and their applications.Trends Analyt. Chem.201810926027410.1016/j.trac.2018.10.011
     [Google Scholar]
  68. DewanjeeS. JoardarS. BhattacharjeeN. DuaT.K. DasS. KalitaJ. MannaP. Edible leaf extract of Ipomoea aquatica Forssk. (Convolvulaceae) attenuates doxorubicin-induced liver injury via inhibiting oxidative impairment, MAPK activation and intrinsic pathway of apoptosis.Food Chem. Toxicol.201710532233610.1016/j.fct.2017.05.002 28478100
     [Google Scholar]
  69. SakrS.A. Abo-El-YazidS.M. Effect of fenugreek seed extract on adriamycin-induced hepatotoxicity and oxidative stress in albino rats.Toxicol. Ind. Health2012281087688510.1177/0748233711425076 22082829
     [Google Scholar]
  70. PrasannaP.L. RenuK. Valsala GopalakrishnanA. New molecular and biochemical insights of doxorubicin-induced hepatotoxicity.Life Sci.202025011759910.1016/j.lfs.2020.117599 32234491
     [Google Scholar]
  71. SpallarossaP. GaribaldiS. AltieriP. FabbiP. MancaV. NastiS. RossettinP. GhigliottiG. BallestreroA. PatroneF. BarsottiA. BrunelliC. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.J. Mol. Cell. Cardiol.200437483784610.1016/j.yjmcc.2004.05.024 15380674
     [Google Scholar]
  72. CohenS.M. LippardS.J. Cisplatin: From DNA damage to cancer chemotherapy.Prog. Nucleic Acid Res. Mol. Biol.2001679313010.1016/S0079‑6603(01)67026‑0 11525387
     [Google Scholar]
  73. KaradenizA. SimsekN. KarakusE. YildirimS. KaraA. CanI. KisaF. EmreH. TurkeliM. Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin.Oxid. Med. Cell. Longev.20112011111010.1155/2011/981793 21904651
     [Google Scholar]
  74. NaqshbandiA. KhanW. RizwanS. KhanF. Studies on the protective effect of flaxseed oil on cisplatin-induced hepatotoxicity.Hum. Exp. Toxicol.201231436437510.1177/0960327111432502 22249395
     [Google Scholar]
  75. AbbasnezhadA. SalamiF. MohebbatiR. A review: Systematic research approach on toxicity model of liver and kidney in laboratory animals.Animal Model. Exp. Med.20225543644410.1002/ame2.12230 35918879
     [Google Scholar]
  76. El-BeshbishyH.A. Lipoic acid attenuates DNA fragmentation, oxidative stress and liver injury induced by tamoxifen in rats. Traditional.Asian Med. (Lieden)200725175188
     [Google Scholar]
  77. AlbukhariA.A. GashlanH.M. El-BeshbishyH.A. NagyA.A. Abdel-NaimA.B. Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats.Food Chem. Toxicol.20094771689169510.1016/j.fct.2009.04.021 19394397
     [Google Scholar]
  78. BjörnssonE. Hepatotoxicity associated with antiepileptic drugs.Acta Neurol. Scand.2008118528129010.1111/j.1600‑0404.2008.01009.x 18341684
     [Google Scholar]
  79. HiguchiS. YanoA. TakaiS. TsuneyamaK. FukamiT. NakajimaM. YokoiT. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury.Toxicol. Sci.2012130141610.1093/toxsci/kfs222 22790970
     [Google Scholar]
  80. Fricke-GalindoI. LLerenaA. Jung-CookH. López-LópezM. Carbamazepine adverse drug reactions.Expert Rev. Clin. Pharmacol.201811770571810.1080/17512433.2018.1486707 29898616
     [Google Scholar]
  81. HenryT.R. The history of valproate in clinical neuroscience.Psychopharmacol Bull200337516(Suppl.2)14624229
     [Google Scholar]
  82. SokmenB.B. TunaliS. YanardagR. Effects of vitamin U (S-methyl methionine sulphonium chloride) on valproic acid induced liver injury in rats.Food Chem. Toxicol.201250103562356610.1016/j.fct.2012.07.056 22889891
     [Google Scholar]
  83. TongV. TengX.W. ChangT.K.H. AbbottF.S. Valproic acid I: Time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.Toxicol. Sci.200586242743510.1093/toxsci/kfi184 15858223
     [Google Scholar]
  84. BehlM. NyskaA. ChhabraR.S. TravlosG.S. FombyL.M. SparrowB.R. HejtmancikM.R. ChanP.C. Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava.Food Chem. Toxicol.201149112820282910.1016/j.fct.2011.07.067 21871523
     [Google Scholar]
  85. Pinazo-BanderaJ.M. García-CortésM. Segovia-ZafraA. LucenaM.I. AndradeR.J. Recreational drugs and the risk of hepatocellular carcinoma.Cancers20221421539510.3390/cancers14215395 36358813
     [Google Scholar]
  86. AnsteeQ.M. GoldinR.D. Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research.Int. J. Exp. Pathol.200687111610.1111/j.0959‑9673.2006.00465.x 16436109
     [Google Scholar]
  87. JahnD. KircherS. HermannsH.M. GeierA. Animal models of NAFLD from a hepatologist’s point of view.Biochim. Biophys. Acta Mol. Basis Dis.20191865594395310.1016/j.bbadis.2018.06.023 29990551
     [Google Scholar]
  88. BertolaA. Rodent models of fatty liver diseases.Liver Res.20182131310.1016/j.livres.2018.03.001
     [Google Scholar]
  89. SanthekadurP.K. KumarD.P. SanyalA.J. Preclinical models of non-alcoholic fatty liver disease.J. Hepatol.201868223023710.1016/j.jhep.2017.10.031 29128391
     [Google Scholar]
  90. GaoB. XuM.J. BertolaA. WangH. ZhouZ. LiangpunsakulS. Animal models of alcoholic liver disease: pathogenesis and clinical relevance.Gene Expr.201717317318610.3727/105221617X695519 28411363
     [Google Scholar]
  91. KaraaA. ThompsonK.J. McKillopI.H. ClemensM.G. SchrumL.W. S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model.Shock200830219720510.1097/SHK.0b013e318160f417 18180699
     [Google Scholar]
  92. MuellerS. MillonigG. SeitzH.K. Alcoholic liver disease and hepatitis C: A frequently underestimated combination.World J. Gastroenterol.2009152834623471 19630099
     [Google Scholar]
  93. AroorA.R. JacksonD.E. ShuklaS.D. Elevated activation of ERK1 and ERK2 accompany enhanced liver injury following alcohol binge in chronically ethanol-fed rats.Alcohol. Clin. Exp. Res.201135122128213810.1111/j.1530‑0277.2011.01577.x 21790671
     [Google Scholar]
  94. OhashiT. NakadeY. IbusukiM. KitanoR. YamauchiT. KimotoS. InoueT. KobayashiY. SumidaY. ItoK. NakaoH. UmezawaK. YonedaM. Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice.PLoS One2019141e021006810.1371/journal.pone.0210068 30689650
     [Google Scholar]
  95. ZhongF. ZhouX. XuJ. GaoL. Rodent models of nonalcoholic fatty liver disease.Digestion2020101552253510.1159/000501851 31600750
     [Google Scholar]
  96. JensenV.S. HvidH. DamgaardJ. NygaardH. IngvorsenC. WulffE.M. LykkesfeldtJ. FledeliusC. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague–Dawley rats.Diabetol. Metab. Syndr.2018101410.1186/s13098‑018‑0307‑8 29410708
     [Google Scholar]
  97. AsgharpourA. CazanaveS.C. PacanaT. SeneshawM. VincentR. BaniniB.A. KumarD.P. DaitaK. MinH.K. MirshahiF. BedossaP. SunX. HoshidaY. KoduruS.V. ContaiferD. WarnckeU.O. WijesingheD.S. SanyalA.J. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.J. Hepatol.201665357958810.1016/j.jhep.2016.05.005 27261415
     [Google Scholar]
  98. HansenH.H. FeighM. VeidalS.S. RigboltK.T. VrangN. FosgerauK. Mouse models of nonalcoholic steatohepatitis in preclinical drug development.Drug Discov. Today201722111707171810.1016/j.drudis.2017.06.007 28687459
     [Google Scholar]
  99. NevzorovaY.A. Boyer-DiazZ. CuberoF.J. Gracia-SanchoJ. Animal models for liver disease – A practical approach for translational research.J. Hepatol.202073242344010.1016/j.jhep.2020.04.011 32330604
     [Google Scholar]
  100. KawasakiT. IgarashiK. KoedaT. SugimotoK. NakagawaK. HayashiS. YamajiR. InuiH. FukusatoT. YamanouchiT. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis.J. Nutr.2009139112067207110.3945/jn.109.105858 19776184
     [Google Scholar]
  101. NanjiA.A. Animal models of nonalcoholic fatty liver disease and steatohepatitis.Clin. Liver Dis.200483559574, ix10.1016/j.cld.2004.04.00215331064
     [Google Scholar]
  102. D’Souza El-GuindyN.B. KovacsE.J. De WitteP. SpiesC. LittletonJ.M. De VilliersW.J.S. LottA.J. PlackettT.P. LanzkeN. MeadowsG.G. Laboratory models available to study alcohol-induced organ damage and immune variations: Choosing the appropriate model.Alcohol. Clin. Exp. Res.20103491489151110.1111/j.1530‑0277.2010.01234.x 20586763
     [Google Scholar]
  103. ThieleT.E. CrabbeJ.C. BoehmS.L. “Drinking in the Dark” (DID): a simple mouse model of binge-like alcohol intake.Curr. Protoc Neurosci.201468149.11210.1002/0471142301.ns0949s6824984686
     [Google Scholar]
  104. BakiriL. WagnerE.F. Mouse models for liver cancer.Mol. Oncol.20137220622310.1016/j.molonc.2013.01.005 23428636
     [Google Scholar]
  105. Lamas-PazA. HaoF. NelsonL.J. VázquezM.T. CanalsS. MoralM.G. Martínez-NavesE. NevzorovaY.A. CuberoF.J. Alcoholic liver disease: Utility of animal models.World J. Gastroenterol.201824455063507510.3748/wjg.v24.i45.5063 30568384
     [Google Scholar]
  106. McCaskillM.L. HottorH.T. SapkotaM. WyattT.A. Dietary diallyl disulfide supplementation attenuates ethanol-mediated pulmonary vitamin D speciate depletion in C57Bl/6 mice.BMC Nutr.2015111810.1186/s40795‑015‑0012‑z 27536382
     [Google Scholar]
  107. LiangpunsakulS. RahminiY. RossR.A. ZhaoZ. XuY. CrabbD.W. Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice.Am. J. Physiol. Gastrointest. Liver Physiol.20123025G515G52310.1152/ajpgi.00455.2011 22194417
     [Google Scholar]
  108. GeorgievP. JochumW. HeinrichS. JangJ.H. NocitoA. DahmF. ClavienP-A. Characterization of time-related changes after experimental bile duct ligation.Br. J. Surg.200895564665610.1002/bjs.6050 18196571
     [Google Scholar]
  109. HeinrichS. GeorgievP. WeberA. VergopoulosA. GrafR. ClavienP.A. Partial bile duct ligation in mice: A novel model of acute cholestasis.Surgery2011149344545110.1016/j.surg.2010.07.046 20817234
     [Google Scholar]
  110. AllerM.A. DuranM. OrtegaL. AriasJ.L. NavaM.P. PrietoI. AriasJ. Comparative study of macro‐ and microsurgical extrahepatic cholestasis in the rat.Microsurgery200424644244710.1002/micr.10153 15389969
     [Google Scholar]
  111. AllerM.A. NavaM.P. AriasJ.L. DuránM. PrietoI. LlamasM.A. AriasJ. Microsurgical extrahepatic cholestasis in the rat: a long-term study.J. Invest. Surg.20041729910410.1080/08941930490422537 15204716
     [Google Scholar]
  112. TanakaA. LeungP.S.C. YoungH.A. GershwinM.E. Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans.Arch. Med. Sci.2018144930940 30002712
     [Google Scholar]
  113. PetersenM. DrewsU. SchweizerP. Induction of bile ducts in embryonic liver by mesenchyme: A new perspective for the treatment of biliary atresia?Eur. J. Pediatr. Surg.200111638239010.1055/s‑2001‑19731 11807667
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002394147251007105422
Loading
Metabolic and Pharmacokinetic Perspectives on Hepatotoxic Agents in Experimental Cirrhosis
Current Drug Metabolism 26, 507 (2025); https://doi.org/10.2174/0113892002394147251007105422
/content/journals/cdm/10.2174/0113892002394147251007105422
/content/journals/cdm/10.2174/0113892002394147251007105422
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): animal models; cirrhosis; dose; drug-induced liver injury; fibrosis; Hepatotoxicity

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test